Suggested remit - To appraise the clinical and cost-effectiveness of acalabrutinib within its marketing authorisation for treating chronic lymphocytic leukaemia
 
Status In progress
Process STA 2018
ID number 1613

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ

Consultees

Companies sponsors AstraZeneca (acalabrutinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Chronic Lymphocytic Leukaemia Support Association
  Leukaemia CARE
  Lymphoma Action
Professional groups Association of Cancer Physicians
  Royal College of Physicians
  Royal College of Radiologists
  UK Chronic Lymphocytic Leukaemia Forum

Commentators

Comparator companies AbbVie (venetoclax) (confidentiality agreement signed, participating)
  Janssen (Ibrutinib) (confidentiality agreement signed, participating)
  Roche (rituximab, obinutuzumab) (confidentiality agreement signed, participating)
  Accord Healthcare (bendamustine, fludarabine) (confidentiality agreement not signed, not participating)
  Actavis UK (fludarabine) (confidentiality agreement not signed, not participating)
  AAH Pharmaceuticals (chlorambucil) (confidentiality agreement not signed, not participating)
  Aspen (chlorambucil) (confidentiality agreement not signed, not participating)
  Baxter healthcare (cyclophosphamide) (confidentiality agreement not signed, not participating)
  Dr Reddy’s Laboratories (bendamustine) (confidentiality agreement not signed, not participating)
  Gilead Sciences (idelalisib) (confidentiality agreement not signed, not participating)
  medac (bendamustine) (confidentiality agreement not signed, not participating)
  Napp Pharmaceuticals (bendamustine, rituximab) (confidentiality agreement not signed, not participating)
  Sandoz (rituximab, cyclophosphamide, fludarabine) (confidentiality agreement not signed, not participating)
  Sanofi (fludarabine) (confidentiality agreement not signed, not participating)
  Seacross Pharmaceuticals (bendamustine) (confidentiality agreement not signed, not participating)
  Zentiva (bendamustine) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
06 March 2020 Invitation to participate
06 March 2020 In progress. In appraisal
09 September 2019 - 04 October 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance